ethyl 2-(3-aminophenyl)propionate | 68285-88-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-(3-aminophenyl)propionate
• 英文别名: (+/-)-2-(3-amino-phenyl)-propionic acid ethyl ester；2-(3-amino-phenyl)-propionic acid ethyl ester；Ethyl 2-(3-aminophenyl)propanoate
• CAS: 68285-88-1
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: XLLSOKOEONACSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-(3-aminophenyl)propionate 在 硫酸 、 水 、 sodium nitrite 作用下， 生成 α-(3-hydroxyphenyl)propionic acid ethyl ester
  参考文献：
  名称：

  Studies on the synthesis and analgesic and anti-inflammatory activities of 2-thiazolylamino- and 2-thiazolyloxy-arylacetic acid derivatives.

  摘要：

  根据Hantzsch方法，通过硫酰胺与卤代乙缩醛的缩合反应制备了一系列2-噻唑基氨基、2-噻唑基氧和2-噻唑基硫代芳基乙酸衍生物，而具有α-甲基芳基乙酸部分的硫酰胺则通过结合已知方法从卤代芳香硝基化合物中方便地获得。在O-苯基硫代氨基甲酸酯（XVIII）与氯代二乙缩醛的模型反应中，分离出无环卤代化合物（XIX）和4-乙氧基-2-苯氧基-2-噻唑啉（XX）等中间体，阐明了苯氧噻唑（XXI）的生成反应途径。通过小鼠的醋酸引起的扭体法和大鼠的角叉菜胶引起的足跖肿胀法，分别评估了所研究化合物的镇痛和抗炎作用。2-[4-（2-噻唑氧基）苯基]丙酸（XIVa）在活性与毒性之间具有最佳的治疗比（在小鼠中）。

  DOI：

  10.1248/cpb.31.3424
• 作为产物：
  描述：

  2-(4-Chloro-3-nitro-phenyl)-propionic acid ethyl ester 在 palladium on activated charcoal 氢气 、 potassium acetate 作用下， 以 乙醇 为溶剂， 以90%的产率得到ethyl 2-(3-aminophenyl)propionate
  参考文献：
  名称：

  Studies on the synthesis and analgesic and anti-inflammatory activities of 2-thiazolylamino- and 2-thiazolyloxy-arylacetic acid derivatives.

  摘要：

  根据Hantzsch方法，通过硫酰胺与卤代乙缩醛的缩合反应制备了一系列2-噻唑基氨基、2-噻唑基氧和2-噻唑基硫代芳基乙酸衍生物，而具有α-甲基芳基乙酸部分的硫酰胺则通过结合已知方法从卤代芳香硝基化合物中方便地获得。在O-苯基硫代氨基甲酸酯（XVIII）与氯代二乙缩醛的模型反应中，分离出无环卤代化合物（XIX）和4-乙氧基-2-苯氧基-2-噻唑啉（XX）等中间体，阐明了苯氧噻唑（XXI）的生成反应途径。通过小鼠的醋酸引起的扭体法和大鼠的角叉菜胶引起的足跖肿胀法，分别评估了所研究化合物的镇痛和抗炎作用。2-[4-（2-噻唑氧基）苯基]丙酸（XIVa）在活性与毒性之间具有最佳的治疗比（在小鼠中）。

  DOI：

  10.1248/cpb.31.3424

文献信息

• Gastrin and cholecystokinin receptor ligands
  申请人：James Black Foundation Limited

  公开号：US06479531B1

  公开（公告）日：2002-11-12

  Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently ═N—, —N(R5)—═CH—, —S— or —O—. n is from 1 to 4; R1 is H or C1 to C15 hydrocarbyl R2 is selected from H, Me, Et, Pr and OH, R3 is selected from H, Me, Et and Pr; or (when n is greater than 1) each R3 is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C3 to C6 carbocylic ring, or R2 and R3 on the same carbon atom together represent an ═O group; R4 is C1 to C15 hydrocarbyl Z is —(NR7)a—CO—(NR8)b— (wherein a is 0 or 1, b is 0 or 1, —CO—NR7—CH2—CO—NR8—, —CO—O—, —CH2—CH2—, —CH═CH—, —CH2—NR8— or a bond; Q is —R9V, or (II), (wherein R9 is —CH2—; —CH2—CH2—; or (III), R9 and R8, together with the nitrogen atom to which R8 is attached, form a piperidine or pyrrolidine ring which is substituted by V; V is —CO—NH—SO2—Ph, —SO2—NH—CO—Ph, —CH2OH, or a group of the formula —R10U, (wherein U is —COOH, tetrazolyl, —CONHOH— or —SO3H; and R10 is a bond; C1 to C6 hydrocarbylene, —O—(C1 to C3 alkylene)—; —SO2NR11—CHR12—; —CO—NR11—CHR12—, or —NH—(CO)c—CH2—, c being 0 or 1).

  化合物的结构式（I）及其药学上可接受的盐是胃泌素和/或胆囊收缩素受体的配体。X和Y独立地为═N—，—N(R5)—═CH—，—S—或—O—。n为1至4；R1为H或C1至C15烃基；R2从H，Me，Et，Pr和OH中选择；R3从H，Me，Et和Pr中选择；或（当n大于1时）每个R3独立地从H，Me，Et和Pr中选择，或相邻碳原子上的两个R3基团连接形成C3至C6碳环，或R2和R3在同一碳原子上共同表示一个═O基团；R4为C1至C15烃基；Z为—(NR7)a—CO—(NR8)b—（其中a为0或1，b为0或1，—CO—NR7—CH2—CO—NR8—，—CO—O—，— — —，—CH═CH—，— —NR8—或键；Q为—R9V，或（II），（其中R9为— —；— — —；或（III），R9和R8，与R8连接的氮原子一起形成被V取代的哌啶或吡咯烷环；V为—CO—NH—SO2—Ph，—SO2—NH—CO—Ph，— OH，或具有式—R10U的基团，（其中U为—COOH，四唑基，—CONHOH—或—SO3H；R10为键；C1至C6烃基亚烷，—O—（C1至C3亚烷基）—；—SO2NR11—CHR12—；—CO—NR11—CHR12—，或—NH—（CO）c— —，其中c为0或1）。
• [EN] GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS<br/>[FR] LIGANDS DES RECEPTEURS DE LA GASTRINE ET DE LA CHOLECYSTOKININE
  申请人：BLACK JAMES FOUNDATION

  公开号：WO2000027823A1

  公开（公告）日：2000-05-18

  Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently =N-, -N(R5)- =CH-, -S- or -O-. n is from 1 to 4; R1 is H or C¿1? to C15 hydrocarbyl R?2¿ is selected from H, Me, Et, Pr and OH, R¿3? is selected from H, Me, Et and Pr; or (when n is greater than 1) each R?3¿ is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C¿3? to C6 carbocylic ring, or R?2 and R3¿ on the same carbon atom together represent an =O group; R4 is C1 to C15 hydrocarbyl Z is -(NR7)a-CO-(NR8)b- (wherein a is 0 or 1, b is 0 or 1, -CO-NR7-CH2-CO-NR8-, -CO-O-, -CH¿2?-CH2-, -CH=CH-, -CH2-NR?8¿- or a bond; Q is -R9V, or (II), (wherein R9 is -CH¿2?-; -CH2-CH2-; or (III), R?9 and R8¿, together with the nitrogen atom to which R8 is attached, form a piperidine or pyrrolidine ring which is substituted by V; V is -CO-NH-SO¿2?-Ph, -SO2-NH-CO-Ph, -CH2OH, or a group of the formula -R?10¿U, (wherein U is -COOH, tetrazolyl, -CONHOH- or -SO¿3?H; and R?10¿ is a bond; C¿1? to C6 hydrocarbylene, -O-(C1 to C3 alkylene)-; -SO2NR?11-CHR12¿-; -CO-NR?11-CHR12¿-, or -NH-(CO)¿c?-CH2-, c being 0 or 1).

  式(I)化合物及其药学上可接受的盐是胃泌素和/或胆囊收缩素受体的配体。X和Y独立地为=N-，-N（R5）-，=CH-，-S-或-O-。n为1至4；R1为H或C1至C15的烃基；R2从H，Me，Et，Pr和OH中选择，R3从H，Me，Et和Pr中选择；或（当n大于1时）每个R3独立地从H，Me，Et和Pr中选择，或相邻碳原子上的两个R3基团连接形成C3至C6的环烷基，或R2和R3在同一碳原子上共同表示一个=O基团；R4为C1至C15的烃基，Z为-(NR7)a-CO-(NR8)b-（其中a为0或1，b为0或1，-CO-NR7-CH2-CO-NR8-，-CO-O-，- - -，-CH=CH-，- -NR8-或键；Q为-R9V，或（II），（其中R9为- -；- - -；或（III），R9和R8，连同R8所连接的氮原子，形成被V取代的哌嗪或吡咯烷环；V为-CO-NH-SO2-Ph，-SO2-NH-CO-Ph，- OH，或式-R10U的基团（其中U为-COOH，四唑基，-CONHOH-或-SO3H；R10为键；C1至C6的烃亚基，-O-（C1至C3的烷基）-；-SO2NR11-CHR12-；-CO-NR11-CHR12-，或-NH-（CO）c- -，其中c为0或1）。
• Design, synthesis and biological evaluation of non-covalent AmpC β-lactamases inhibitors
  作者：Filippo Genovese、Sandra Lazzari、Ettore Venturi、Luca Costantino、Jesus Blazquez、Claudia Ibacache-Quiroga、Maria Paola Costi、Donatella Tondi

  DOI：10.1007/s00044-017-1809-x

  日期：2017.5

  Bacterial resistance represents a worldwide emergency threatening the efficacy of all available antibiotics. Among the several resistance mechanisms developed by bacteria, beta-lactamase enzymes (BLs), which are able to inactivate most beta-lactam core antibiotics, represent a key target to block, thus prolonging antibiotics half-life. Several approaches aimed at inhibiting beta-lactamases have been so far undertaken, mainly involving beta-lactam-like or covalent inhibitors. Applying a structure-based de novo design approach, we recently discovered a novel, non-covalent and competitive inhibitor of AmpC beta-lactamase: lead 1. It has a K-i of 1 mu M, a ligand efficiency of 0.38 kcal mol(-1) and lead-like physical properties. Moreover, it reverts resistance to ceftazidime in bacterial pathogens expressing AmpC and does not up-regulate beta-lactamases expression in cell culture. Its features make it a good candidate for chemical optimization: starting from lead 1 crystallographic complex with AmpC, 11 analogs were designed to complement additional AmpC sites, then synthesized and tested against clinically resistant pathogens. While the new inhibitors maintain similar in vitro activity as the starting lead, some of them, in biological assays, extert a higher potency showing improved synergic activity with ceftazidime in resistant clinically isolated strains.
• GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS
  申请人：JAMES BLACK FOUNDATION LIMITED

  公开号：EP1178969A1

  公开（公告）日：2002-02-13
• US6479531B1
  申请人：——

  公开号：US6479531B1

  公开（公告）日：2002-11-12